Varian John
SEC-identified person · CIK 1416176 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Sellas Life Sciences Group, Inc. gale | Director | filed 2017–2026 |
| Acorda Therapeutics, Inc. ACOR | Director | filed 2022–2023 |
| Zyla Life Sciences ZCOR | Director | filed 2018–2019 |
| Versartis, Inc. VSAR | Director | filed 2014–2017 |
| Xoma Royalty Corp XOMAD | Director · Director and CEO | filed 2008–2017 |
| Aryx Therapeutics, Inc. ARYX | COO & CFO | filed 2007–2010 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.